Research ArticleOriginal Article
Open Access

The protective effect of Astaxanthin on scopolamine - induced Alzheimer’s model in mice

Rania Magadmi, Sara Nassibi, Fatemah Kamel, Aziza R. Al-Rafiah, Duaa Bakhshwin, Maha Jamal, Mohammed Alsieni, Abdulhadi S. Burzangi, M. A. F Zaher and Mohammed Bendary
Neurosciences Journal April 2024, 29 (2) 103-112; DOI: https://doi.org/10.17712/nsj.2024.2.20230060

References

  1. 1.↵
    1. Gauthier S,
    2. Webster C,
    3. Servaes S,
    4. Morais JA
    , Rosa-Neto P. World Alzheimer Report 2022: Life after diagnosis: Navigating treatment, care and support. London (UK): Alzheimer’s Disease International. 2022.
  2. 2.↵
    1. Weller J,
    2. Budson A.
    Current understanding of Alzheimer’s disease diagnosis and treatment. F1000Res 2018; 7: F1000.
    OpenUrl
  3. 3.↵
    1. Princiotta Cariddi L,
    2. Mauri M,
    3. Cosentino M,
    4. Versino M,
    5. Marino F.
    Alzheimer’s Disease: From Immune Homeostasis to Neuroinflammatory Condition. Int J Mol Sci 2022; 23: 13008.
    OpenUrlCrossRef
  4. 4.↵
    1. Gao F,
    2. Wu X,
    3. Mao X,
    4. Niu F,
    5. Zhang B,
    6. Dong J, et al.
    Astaxanthin provides neuroprotection in an experimental model of traumatic brain injury via the Nrf2/HO-1 pathway. Am J Transl Res 2021; 13: 1483–1493.
    OpenUrl
  5. 5.↵
    1. Morris R.
    Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 1984; 11: 47–60.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Ellman GL,
    2. Courtney KD,
    3. Andres V, Jr.,
    4. Feather-Stone RM.
    A new and rapid colorimetric determination of acetylcholinesterase activity. Biochemical pharmacology 1961; 7: 88–95.
    OpenUrlCrossRefPubMedWeb of Science
  7. 7.↵
    1. Kamat PK,
    2. Kalani A,
    3. Rai S,
    4. Swarnkar S,
    5. Tota S,
    6. Nath C, et al.
    Mechanism of Oxidative Stress and Synapse Dysfunction in the Pathogenesis of Alzheimer’s Disease: Understanding the Therapeutics Strategies. Mol Neurobiol 2016; 53: 648–661.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Mostafa DK,
    2. Ismail CA,
    3. Ghareeb DA.
    Differential metformin dose-dependent effects on cognition in rats: role of Akt. Psychopharmacology (Berl) 2016; 233: 2513–24.
    OpenUrl
  9. 9.↵
    1. Rahman SO,
    2. Panda BP,
    3. Parvez S,
    4. Kaundal M,
    5. Hussain S,
    6. Akhtar M, et al.
    Neuroprotective role of astaxanthin in hippocampal insulin resistance induced by Abeta peptides in animal model of Alzheimer’s disease. Biomed Pharmacother 2019; 110: 47–58.
    OpenUrl
  10. 10.↵
    1. Grimmig B,
    2. Kim SH,
    3. Nash K,
    4. Bickford PC,
    5. Douglas Shytle R.
    Neuroprotective mechanisms of astaxanthin: a potential therapeutic role in preserving cognitive function in age and neurodegeneration. Geroscience 2017; 39: 19–32.
    OpenUrl
  11. 11.↵
    1. Xue Z,
    2. Zhao K,
    3. Sun Z,
    4. Wu C,
    5. Yu B,
    6. Kong D, et al.
    Isorhapontigenin ameliorates cerebral ischemia/reperfusion injury via modulating Kinase Cepsilon/Nrf2/HO-1 signaling pathway. Brain Behav 2021; 11: e02143.
    OpenUrl
  12. 12.↵
    1. El-Agamy SE,
    2. Abdel-Aziz AK,
    3. Wahdan S,
    4. Esmat A,
    5. Azab SS.
    Astaxanthin Ameliorates Doxorubicin-Induced Cognitive Impairment (Chemobrain) in Experimental Rat Model: Impact on Oxidative, Inflammatory, and Apoptotic Machineries. Mol Neurobiol 2018; 55: 5727–5740.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Dose J,
    2. Matsugo S,
    3. Yokokawa H,
    4. Koshida Y,
    5. Okazaki S,
    6. Seidel U, et al.
    Free Radical Scavenging and Cellular Antioxidant Properties of Astaxanthin. Int J Mol Sci 2016; 17: 103.
    OpenUrl
  14. 14.↵
    1. Galasso C,
    2. Orefice I,
    3. Pellone P,
    4. Cirino P,
    5. Miele R,
    6. Ianora A, et al.
    On the Neuroprotective Role of Astaxanthin: New Perspectives? Marine drugs 2018; 16: 247.
    OpenUrl
  15. 15.↵
    1. Fanaee-Danesh E,
    2. Gali CC,
    3. Tadic J,
    4. Zandl-Lang M,
    5. Carmen Kober A,
    6. Agujetas VR, et al.
    Astaxanthin exerts protective effects similar to bexarotene in Alzheimer’s disease by modulating amyloid-beta and cholesterol homeostasis in blood-brain barrier endothelial cells. Biochim Biophys Acta Mol Basis Dis 2019; 1865: 2224–2245.
    OpenUrl
  16. 16.↵
    1. Terry AV Jr.,
    2. Buccafusco JJ.
    The cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 2003; 306: 821–827.
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    1. Maurer SV,
    2. Williams CL.
    The Cholinergic System Modulates Memory and Hippocampal Plasticity via Its Interactions with Non-Neuronal Cells. Front Immunol 2017; 8: 1489.
    OpenUrl
  18. 18.↵
    1. Kwon SH,
    2. Ma SX,
    3. Joo HJ,
    4. Lee SY,
    5. Jang CG.
    Inhibitory Effects of Eucommia ulmoides Oliv. Bark on Scopolamine-Induced Learning and Memory Deficits in Mice. Biomol Ther (Seoul) 2013; 21: 462–469.
    OpenUrl
  19. 19.↵
    1. Chen MH,
    2. Wang TJ,
    3. Chen LJ,
    4. Jiang MY,
    5. Wang YJ,
    6. Tseng GF, et al.
    The effects of astaxanthin treatment on a rat model of Alzheimer’s disease. Brain Res Bull 2021; 172: 151–63.
    OpenUrl
  20. 20.↵
    1. Che H,
    2. Li Q,
    3. Zhang T,
    4. Wang D,
    5. Yang L,
    6. Xu J, et al.
    Effects of Astaxanthin and Docosahexaenoic-Acid-Acylated Astaxanthin on Alzheimer’s Disease in APP/PS1 Double-Transgenic Mice. J Agric Food Chem 2018; 66: 4948–4957.
    OpenUrl
  21. 21.↵
    1. Al-Amin MM,
    2. Reza HM,
    3. Saadi HM,
    4. Mahmud W,
    5. Ibrahim AA,
    6. Alam MM, et al.
    Astaxanthin ameliorates aluminum chloride-induced spatial memory impairment and neuronal oxidative stress in mice. Eur J Pharmacol 2016; 777: 60–69.
    OpenUrl
  22. 22.↵
    1. Yang X,
    2. Wei HM,
    3. Hu GY,
    4. Zhao J,
    5. Long LN,
    6. Li CJ, et al.
    Combining antioxidant astaxantin and cholinesterase inhibitor huperzine A boosts neuroprotection. Mol Med Rep 2020; 21: 1043–1050.
    OpenUrl
  23. 23.↵
    1. Ohgami K,
    2. Shiratori K,
    3. Kotake S,
    4. Nishida T,
    5. Mizuki N,
    6. Yazawa K, et al.
    Effects of astaxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo. Invest Ophthalmol Vis Sci 2003; 44: 2694–2701.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Suzuki Y,
    2. Ohgami K,
    3. Shiratori K,
    4. Jin XH,
    5. Ilieva I,
    6. Koyama Y, et al.
    Suppressive effects of astaxanthin against rat endotoxin-induced uveitis by inhibiting the NF-kappaB signaling pathway. Exp Eye Res 2006; 82: 275–281.
    OpenUrlCrossRefPubMedWeb of Science
  25. 25.↵
    1. Kim YH,
    2. Koh HK,
    3. Kim DS.
    Down-regulation of IL-6 production by astaxanthin via ERK-, MSK-, and NF-kappaB-mediated signals in activated microglia. Int Immunopharmacol 2010; 10: 1560–1572.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Krstic D,
    2. Madhusudan A,
    3. Doehner J,
    4. Vogel P,
    5. Notter T,
    6. Imhof C, et al.
    Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. J Neuroinflammation 2012; 9: 151.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Wu CR,
    2. Chang CL,
    3. Hsieh PY,
    4. Lin LW,
    5. Ching H.
    Psoralen and isopsoralen, two coumarins of Psoraleae Fructus, can alleviate scopolamine-induced amnesia in rats. Planta Med 2007; 73: 275–278.
    OpenUrlPubMed
  28. 28.↵
    1. Moosavi F,
    2. Hosseini R,
    3. Saso L,
    4. Firuzi O.
    Modulation of neurotrophic signaling pathways by polyphenols. Drug Des Devel Ther 2016; 10: 23–42.
    OpenUrlPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section